Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs

NCT00227422 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00227422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
November 30, 2005
Enrollment
324
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal